1887

Abstract

Recent studies have generated interest in the function of human adenovirus serotype 5 (HAdV-5) hexon:  factor X (FX) binding and subsequent hepatocyte transduction and interaction with the immune system. Here, we retargeted adenovirus serotype 5 vectors, ablated for FX interaction, by replacing amino acids in hexon HVR7 with RGD-4C or inserting the peptide into the fibre HI loop. These genetic modifications in the capsid were compatible with virus assembly, and could efficiently retarget transduction of the vector via the αvβ3/5 integrin-mediated pathway, but did not alter immune recognition by pre-existing human neutralizing anti-HAdV-5 antibodies or by natural antibodies in mouse serum. Thus, FX-binding-ablated HAdV-5 can be retargeted but remain sensitive to immune-mediated attack. These findings further refine HAdV-5-based vectors for human gene therapy and inform future vector development.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/jgv.0.000505
2016-08-01
2020-04-02
Loading full text...

Full text loading...

/deliver/fulltext/jgv/97/8/1911.html?itemId=/content/journal/jgv/10.1099/jgv.0.000505&mimeType=html&fmt=ahah

References

  1. Alba R., Bradshaw A. C., Parker A. L., Bhella D., Waddington S. N., Nicklin S. A., van Rooijen N., Custers J., Goudsmit J. et al. 2009; Identification of coagulation factor (F)X binding sites on the adenovirus serotype 5 hexon: effect of mutagenesis on FX interactions and gene transfer. Blood114:965–971 [CrossRef][PubMed]
    [Google Scholar]
  2. Alba R., Bradshaw A. C., Coughlan L., Denby L., McDonald R. A., Waddington S. N., Buckley S. M., Greig J. A., Parker A. L. et al. 2010; Biodistribution and retargeting of FX-binding ablated adenovirus serotype 5 vectors. Blood116:2656–2664 [CrossRef][PubMed]
    [Google Scholar]
  3. Atoda H., Ishikawa M., Mizuno H., Morita T.. 1998; Coagulation factor X-binding protein from Deinagkistrodon acutus venom is a Gla domain-binding protein. Biochemistry37:17361–17370 [CrossRef][PubMed]
    [Google Scholar]
  4. Bergelson J. M., Cunningham J. A., Droguett G., Kurt-Jones E. A., Krithivas A., Hong J. S., Horwitz M. S., Crowell R. L., Finberg R. W.. 1997; Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science275:1320–1323 [CrossRef][PubMed]
    [Google Scholar]
  5. Cannistra S. A., Ottensmeier C., Niloff J., Orta B., DiCarlo J.. 1995; Expression and function of beta 1 and alpha v beta 3 integrins in ovarian cancer. Gynecol Oncol58:216–225 [CrossRef][PubMed]
    [Google Scholar]
  6. Dmitriev I., Krasnykh V., Miller C. R., Wang M., Kashentseva E., Mikheeva G., Belousova N., Curiel D. T.. 1998; An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J Virol72:9706–9713[PubMed]
    [Google Scholar]
  7. George S. J., Wan S., Hu J., MacDonald R., Johnson J. L., Baker A. H.. 2011; Sustained reduction of vein graft neointima formation by ex vivo TIMP-3 gene therapy. Circulation124:S135–S142 [CrossRef][PubMed]
    [Google Scholar]
  8. Guo L., Zhang F., Cai Y., Liu T.. 2009; Expression profiling of integrins in lung cancer cells. Pathol Res Pract205:847–853 [CrossRef][PubMed]
    [Google Scholar]
  9. Hofherr S. E., Shashkova E. V., Weaver E. A., Khare R., Barry M. A.. 2008; Modification of adenoviral vectors with polyethylene glycol modulates in vivo tissue tropism and gene expression. Mol Ther16:1276–1282 [CrossRef][PubMed]
    [Google Scholar]
  10. Huard J., Lochmüller H., Acsadi G., Jani A., Massie B., Karpati G.. 1995; The route of administration is a major determinant of the transduction efficiency of rat tissues by adenoviral recombinants. Gene Ther2:107–115[PubMed]
    [Google Scholar]
  11. Kalyuzhniy O., Di Paolo N. C., Silvestry M., Hofherr S. E., Barry M. A., Stewart P. L., Shayakhmetov D. M.. 2008; Adenovirus serotype 5 hexon is critical for virus infection of hepatocytes in vivo. Proc Natl Acad Sci U S A105:5483–5488 [CrossRef][PubMed]
    [Google Scholar]
  12. Krasnykh V., Dmitriev I., Mikheeva G., Miller C. R., Belousova N., Curiel D. T.. 1998; Characterization of an adenovirus vector containing a heterologous peptide epitope in the HI loop of the fiber knob. J Virol72:1844–1852[PubMed]
    [Google Scholar]
  13. Ma J., Duffy M. R., Deng L., Dakin R. S., Uil T., Custers J., Kelly S. M., McVey J. H., Nicklin S. A. et al. 2015; Manipulating adenovirus hexon hypervariable loops dictates immune neutralisation and coagulation factor X-dependent cell interaction in vitro and in vivo. PLoS Pathog11:e1004673 [CrossRef][PubMed]
    [Google Scholar]
  14. Mizuno H., Fujimoto Z., Atoda H., Morita T.. 2001; Crystal structure of an anticoagulant protein in complex with the Gla domain of factor X. Proc Natl Acad Sci U S A98:7230–7234 [CrossRef][PubMed]
    [Google Scholar]
  15. Parker A. L., Waddington S. N., Buckley S. M., Custers J., Havenga M. J., van Rooijen N., Goudsmit J., McVey J. H., Nicklin S. A. et al. 2009; Effect of neutralizing sera on factor X-mediated adenovirus serotype 5 gene transfer. J Virol83:479–483 [CrossRef][PubMed]
    [Google Scholar]
  16. Parker A. L., White K. M., Lavery C. A., Custers J., Waddington S. N., Baker A. H.. 2013; Pseudotyping the adenovirus serotype 5 capsid with both the fibre and penton of serotype 35 enhances vascular smooth muscle cell transduction. Gene Ther20:1158–1164 [CrossRef][PubMed]
    [Google Scholar]
  17. Pasqualini R., Koivunen E., Ruoslahti E.. 1997; Alpha v integrins as receptors for tumor targeting by circulating ligands. Nat Biotechnol15:542–546 [CrossRef][PubMed]
    [Google Scholar]
  18. Reynolds P., Dmitriev I., Curiel D.. 1999; Insertion of an RGD motif into the HI loop of adenovirus fiber protein alters the distribution of transgene expression of the systemically administered vector. Gene Ther6:1336–1339 [CrossRef][PubMed]
    [Google Scholar]
  19. Southgate K., Newby A. C.. 1990; Serum-induced proliferation of rabbit aortic smooth muscle cells from the contractile state is inhibited by 8-Br-cAMP but not 8-Br-cGMP. Atherosclerosis82:113–123 [CrossRef][PubMed]
    [Google Scholar]
  20. Soyombo A. A., Angelini G. D., Bryan A. J., Jasani B., Newby A. C.. 1990; Intimal proliferation in an organ culture of human saphenous vein. Am J Pathol137:1401–1410[PubMed]
    [Google Scholar]
  21. Tomko R. P., Xu R., Philipson L.. 1997; HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proc Natl Acad Sci U S A94:3352–3356 [CrossRef][PubMed]
    [Google Scholar]
  22. Vigne E., Mahfouz I., Dedieu J. F., Brie A., Perricaudet M., Yeh P.. 1999; RGD inclusion in the hexon monomer provides adenovirus type 5-based vectors with a fiber knob-independent pathway for infection. J Virol73:5156–5161[PubMed]
    [Google Scholar]
  23. Waddington S. N., McVey J. H., Bhella D., Parker A. L., Barker K., Atoda H., Pink R., Buckley S. M., Greig J. A. et al. 2008; Adenovirus serotype 5 hexon mediates liver gene transfer. Cell132:397–409 [CrossRef][PubMed]
    [Google Scholar]
  24. Xu Z., Qiu Q., Tian J., Smith J. S., Conenello G. M., Morita T., Byrnes A. P.. 2013; Coagulation factor X shields adenovirus type 5 from attack by natural antibodies and complement. Nat Med19:452–457 [CrossRef][PubMed]
    [Google Scholar]
  25. Zitzmann S., Ehemann V., Schwab M.. 2002; Arginine-glycine-aspartic acid (RGD)-peptide binds to both tumor and tumor- endothelial cells in vivo. Cancer Res62:5139–5143[PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/jgv.0.000505
Loading
/content/journal/jgv/10.1099/jgv.0.000505
Loading

Data & Media loading...

Most cited this month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error